๐Ÿ‡ฎ๐Ÿ‡ชIreland
16ยฐC Partly Cloudy ยท Dublin
Live Updates
--:--:-- IST
Writer Login
Latest
Priya Life Science Clinical trial register
TrackersDrugsComparisonsAPI
Trackers Clinical trials Shanghai
Clinical trial register · China

Clinical Trials in Shanghai, 2026

Every study on the ClinicalTrials.gov registry that lists a site in China and is open, about to open, active-but-closed, or enrolling by invitation. Filter it, cite it, and take it away as a file.

Download CSV
Source: ClinicalTrials.gov, U.S. National Library of Medicine. Complete coverage โ€” all 19052 matching records held by the registry are in this view. Synced 22 Sep 2026, 11:10 UTC
19052
Studies in scope
all four open statuses
11786
Recruiting now
open to new participants
2009
Lead sponsors
across recruiting studies
Top sites
Shanghai 454 Fuzhou 9 Hangzhou 8 Zhengzhou 7 Yangzhou 5
Narrow the registerReset
Recruitment status
Phase
Site location
Shanghai454 Fuzhou9 Hangzhou8 Zhengzhou7 Yangzhou5
All 52 locations
Target enrolment
to

Trials with a site in Shanghai

454 of 19052 studies
Download
Status
Study
Lead sponsor
Phase
Enrol
Chinese sites
Start
Not yet open
Correlation Between Artificial Intelligence-Based Fecal Coverage Area-Quantified Bowel Preparation Quality Score (FQ-BBPS) and Adenoma Detection Rate
NCT07795788Colorectal Adenoma
Fudan University
Observational
560
Shanghai
2026-10-01
Not yet open
ctDNA-Guided Chemotherapy Omission With Ribociclib Plus Endocrine Therapy in HR-Positive/HER2-Negative Breast Cancer
NCT07423611Breast Cancer
Fudan University
Phase 2
388
Shanghai
2026-10-01
Recruiting
1-Week Versus 3-Week PBI
NCT07832279Early-Stage Breast Cancer
Fudan University
Not applicable
818
Shanghai
2026-10
Not yet open
The Study Of Andamertinib Plus Anlotinib In Patients With Locally Advanced or Metastatic Non-Small Cell Lung Cancer
NCT07780578Non-Small Cell Lung Cancer (NSCLC, Locally Advanced or Metastatic, Second-line
Fudan University
Phase 2
34
Shanghai
2026-09-30
Not yet open
Cryoablation Combined With QL1706 (Iparomlimab/Tuvonralimab) Plus Lenvatinib in Patients With Advanced Biliary Tract Cancer.
NCT07829874Biliary Tract Cancer (BTC)
Fudan University
Phase 2
180
Shanghai
2026-09-20
Recruiting
Response-Adapted Omission of Nodal Boost In N3 Breast Cancer After Neoadjuvant Systemic Therapy
NCT07829848Breast Cancer
Fudan University
Not applicable
534
Shanghai
2026-09-12
Not yet open
Protein-Matched ADC or PDC Umbrella Trial in Advanced Pancreatic and Breast Cancer
NCT07825753Advanced or Metastatic Pancreatic Adenocarcinoma, Advanced or Metastatic Breast Cancer (BC)
Fudan University
Phase 2
225
Shanghai
2026-09-10
Not yet open
Induction PD-1 Inhibitor and Chemotherapy Followed by Chemoradiotherapy in Unresectable or Inoperable HPV-negative LA-HNSCC
NCT07776340HPV-unrelated Head and Neck Squamous Cell Carcinoma
Fudan University
Phase 2
104
Shanghai
2026-09-01
Recruiting
Omission of Adjuvant Radiotherapy in Young Low-Risk Ductal Carcinoma In Situ Following Breast-Conserving Surgery
NCT07762924Ductal Carcinoma In Situ, DCIS
Fudan University
Phase 2
234
Shanghai
2026-09-01
Not yet open
FAPI-Guided Radiotherapy With Cadonilimab and Standard Chemotherapy for Colorectal Peritoneal Metastasis: A Phase III Randomized Controlled Trial (TORHC-PM02)
NCT07815834Colon Rectal Cancer Adenocarcinoma, Peritoneal (Metastatic) Cancer, Second-line Treatment, Radiation Therapy
Fudan University
Phase 3
198
Shanghai
2026-09-01
Recruiting
A Study of Becotatug Vedotin Combined With Pucotenlimab in the Treatment of EGFR-Positive Advanced Penile Cancer
NCT07497919Penile Cancer
Fudan University
Phase 2
20
Shanghai
2026-09-01
Not yet open
Induction Chemotherapy Response-Guided Reduced-Dose Radiotherapy for Nasopharyngeal Carcinoma
NCT07789158Nasopharyngeal Carcinoma (NPC)
Fudan University
Phase 2
269
Shanghai
2026-09-01
Not yet open
GELAD-Based Response-Adapted Treatment for Early-Stage Extranodal NK/T-Cell Lymphoma
NCT07768943Natural Killer/T-cell Lymphoma
Fudan University
Phase 2
620
Shanghai
2026-09-01
Not yet open
AI-Assisted Patient Support in mHSPC
NCT07804030Metastatic Prostate Cancer
Fudan University
Not applicable
160
Fuzhou, Shanghai, Kunming, Wenzhou
2026-09
Not yet open
A Multicenter, Single Arm Study to Evaluate the Preliminary Efficacy and Safety Profile of Inavolisib in Previously Treated Pancreatic Ductal Adenocarcinoma Patients
NCT07694973Pancreatic Ductal Adenocarcinoma (PDAC)
Fudan University
Phase 2
62
Shanghai
2026-08-29
Recruiting
Selective Coverage Versus Comprehensive Coverage Radiotherapy in Poorly Differentiated and Anaplastic Thyroid Cancer
NCT07777536Thyroid Cancer
Fudan University
Phase 2
72
Shanghai
2026-08-12
Recruiting
Dynamic Risk-adapted EBV-DNA and MRI-guided De-concurrent Chemotherapy in Nasopharyngeal Carcinoma
NCT07762976Nasopharyngeal Carcinoma (NPC)
Fudan University
Phase 2
148
Shanghai
2026-08
Not yet open
Response-adapted Postoperative Radiotherapy In Locally Advanced Head and Neck Cancer
NCT07780877Head & Neck Squamous Cell Carcinoma, Locally Advanced Head and Neck Squamous Cell Carcinoma
Fudan University
Phase 2
85
Changsha, Shanghai
2026-08
Not yet open
Romiplostim N01 for Injection for Secondary Prophylaxis of CIT in Breast Cancer
NCT07771881Thrombocytopenia Chemotherapy Induced
Fudan University
Phase 2
53
Shanghai
2026-08
Recruiting
Real-World Study of Young Patients With Solid Tumors in China
NCT07708935Cancer
Fudan University
Observational
12,000
Shanghai
2026-07-31
By invitation
Abemaciclib Combined With FOLFOX/FOLFIRI Regimen in Patients With Advanced Colorectal Liver Metastases Cancer
NCT07441369Liver Metastases From Colorectal Cancer (mCRC)
Fudan University
Phase 2
16
Shanghai
2026-07-30
Not yet open
Sacituzumab Tirumotecan vs MMAE-ADCs in Advanced Urothelial Carcinoma (FUSCC-SPARE-UC-01)
NCT07662863Bladder Cancer, Metastatic Urothelial Carcinoma, Urothelial Carcinoma, Peripheral Neuropathy
Fudan University
Phase 2
75
Shanghai
2026-07-15
Recruiting
PD-1 Inhibitors Combined With Local Therapy at Different Timings in Oligometastatic ESCC
NCT07697859Esophageal Squamous Cell Carcinoma (ESCC)
Fudan University
Observational
354
Shanghai
2026-07-15
Active, closed
The Role of Total Abdominal Autonomic Nerve Preservation During the Resection of Right/Left Colon Cancer: Prospective Clinical Trial
NCT07825766Colon Cancer, Nerve Preserve
Fudan University
Observational
200
Shanghai
2026-07-01
Recruiting
Omission of Adjuvant Radiotherapy in Low- and Intermediate-Risk Ductal Carcinoma In Situ After Breast-Conserving Surgery
NCT07762885Ductal Carcinoma In Situ, DCIS
Fudan University
Phase 3
636
Shanghai
2026-07-01
Not yet open
Dietary Pattern Intervention for Neurodevelopment in Preterm Infants
NCT07702734Preterm, Neurodevelopmental Disorders, Dysbiosis
Fudan University
Not applicable
116
Shanghai
2026-07-01
Not yet open
Neoadjuvant Imlunestrant Plus Abemaciclib Treatment Guided by Ki67 Index After 2 Weeks for ER-Positive HER2-Negative Breast Cancer
NCT07410559Breast Cancer
Fudan University
Phase 2
189
Shanghai
2026-07-01
Not yet open
Iparomlimab and Tovorilimab (QL1706) Combined With Bevacizumab and Chemotherapy as Neoadjuvant Therapy for Advanced Ovarian Cancer
NCT07663513Ovarian Cancers
Fudan University
Phase 2
36
Shanghai
2026-07
Active, closed
Nectin-4 PET to Predict Response to Nectin-4-Targeted Therapy in Advanced Breast Cancer
NCT07708922Breast Cancer Metastatic
Fudan University
Observational
40
Shanghai
2026-06-30
Not yet open
Savolitinib Plus Cetuximab and FOLFOX Chemotherapy for RAS/BRAF Wild-type Metastatic Colorectal Cancer
NCT07683403Colorectal Cancer (CRC)
Fudan University
Phase 1/2
138
Shanghai
2026-06-30
Not yet open
The Effects of Different Anesthetics on the Brain's Neural Networks
NCT07644663Electroencephalogram (EEG), Anesthesia
Fudan University
Phase 4
120
Shanghai
2026-06-09
Not yet open
Probiotics Supplementation for Neurodevelopment in Preterm Infants
NCT07617181Premature Birth, Neurodevelopmental Disorders, Dysbiosis
Fudan University
Not applicable
116
Shanghai
2026-06
Not yet open
Neoadjuvant Moderately Hypofractionated Radiotherapy Combined With Chemotherapy and Immunotherapy for High-risk pMMR/MSS Locally Advanced Rectal Cancer: A Prospective, Multi-center Randomized Control Phase II Trial
NCT07527520Rectal Cancer, Moderately Hypofractionated Radiotherapy, Serplulimab, pMMR/MSS
Fudan University
Phase 2
165
Shanghai
2026-06
Recruiting
Multicentric Database for KRAS Mutant Pancreatic Cancer
NCT07557849Pancreatic Cancer
Fudan University
Observational
1,000
Shanghai
2026-05-22
Not yet open
Sac-TMT Sequential Capecitabine Versus Capecitabine in Early-Stage High-Risk Triple-Negative Breast Cancer Without BRCA Mutations
NCT07628504Adjuvant Drug Therapy
Fudan University
Phase 3
420
Shanghai
2026-05-18
Recruiting
Real-world Patient-reported Outcome of Sacituzumab Govitecan in Chinese Metastatic Breast Cancer
NCT07551050TNBC - Triple-Negative Breast Cancer
Fudan University
Observational
300
Shanghai
2026-05-15
Recruiting
Association Between Screening Behaviors and Lung Cancer Spectrum
NCT07626177Lung Cancer
Fudan University
Observational
5,390
Shanghai
2026-05-14
Recruiting
A Phase II Randomized Trial of Serplulimab With Second-Line Chemo/Targeted Therapy for Early Relapse Colorectal Cancer After Adjuvant Chemotherapy
NCT07604909Colorectal Cancer, Relapse
Fudan University
Phase 2
40
Shanghai
2026-05-10
Recruiting
Opportunistic Breast Cancer Screening Using Non-Contrast Chest CT
NCT07557654Breast Cancer
Fudan University
Observational
5,000
Shanghai
2026-05-06
Recruiting
Artificial Intelligence Model-Guided Neoadjuvant Anti-HER2 Targeted Therapy
NCT07528716Breast Cancer
Fudan University
Phase 3
280
Shanghai
2026-05-06
Recruiting
Comparison of Perioperative Immunotherapy, Adjuvant Immunotherapy or Neoadjuvant Immunotherapy for Resectable Stage II-IIIA NSCLC
NCT07554846Resectable Stage II-IIIa NSCLC
Fudan University
Phase 3
759
Shanghai
2026-05-01
Not yet open
SCRT Based iTNT vs. LCRT Based TNT for MSS Locally Advanced Rectal Cancer
NCT07551479Locally Advanced Rectal Cancer (LARC), MSS (Microsatellite Stable)
Fudan University
Phase 3
612
Shanghai
2026-05-01
Not yet open
Rezvilutamide With Radical Prostatectomy and Metastasis-Directed Therapy in Oligometastatic Prostate Cancer
NCT07490210Oligometastatic Prostate Cancer
Fudan University
Phase 2
300
Shanghai
2026-05-01
By invitation
Anemia on Sublingual Microcirculation in GDFT
NCT07583927Anemia in Patients Undergoing Gastric Cancer Surgery Under Goal-directed Fluid Therapy, Macro-microcirculation Uncoupling
Fudan University
Observational
54
Shanghai
2026-05
Recruiting
Becotatug Vedotin ยฑ Anti-PD-1 in Pretreated Advanced ESCC
NCT07403136Esophageal Squamous Cell Carcinoma
Fudan University
Phase 2
104
Shanghai
2026-04-30
Recruiting
Becotatug Vedotin (MRG003) in Previously Treated Advanced Hepatocellular Carcinoma
NCT07536789Hepato Cellular Carcinoma (HCC)
Fudan University
Phase 2
40
Shanghai
2026-04-17
Recruiting
Clinical Study on the Safety, Efficacy, and Exploration of Immune Mechanisms of a Combined Multimodal Tumor Therapy System for Hepatic Malignancies
NCT07459309Liver Cancer (Primary and Metastatic), Liver Ablation
Fudan University
Not applicable
20
Shanghai
2026-04-13
By invitation
Stereotactic Body Radiotherapy for the Treatment of Distant Metastases in Thyroid Cancer: A Phase II Prospective Clinical Study
NCT07755423Thyroid Cancer Stage IV
Fudan University
Observational
44
Shanghai
2026-04-01
Recruiting
Trastuzumab Deruxtecan Plus ivonescImab for Hormone Receptor-positive HER2 Negative Advanced Breast Cancer Study
NCT07647016Breast Cancer
Fudan University
Phase 2
53
Shanghai
2026-04-01
Not yet open
Iparomlimab Plus Tovorilimab Combined With Bevacizumab and Chemotherapy as First-Line Treatment for Advanced Mesothelioma
NCT07514793Mesothelioma
Fudan University
Phase 2
37
Shanghai
2026-04
Recruiting
Air Purifier Use and Respiratory Health in COPD Patients
NCT07505602Respiratory Health
Fudan University
Not applicable
120
Shanghai
2026-03-30
Recruiting
A Phase II Clinical Study of Multimodal Ablation Combined With Systemic Drug Therapy for Advanced Solid Tumors.
NCT06889610Triple Negative Breast Cancer Metastatic, Melanoma Metastatic, Colorectal Cancer Metastatic
Fudan University
Phase 2
95
Shanghai
2026-03-30
Recruiting
Golidocitinib Versus Placebo as Maintenance Therapy for Peripheral T-Cell Lymphoma
NCT07300514Maintenance Treatment of Peripheral T-cell Lymphoma
Fudan University
Phase 3
136
Shanghai
2026-03-27
Recruiting
Digital Mind-Body Therapy for Neoadjuvant Breast Cancer
NCT07541664Neoadjuvant Therapy
Fudan University
Not applicable
66
Shanghai
2026-03-25
Not yet open
Study of Multi-mode Thermal Therapy Combined With Immunotherapy In Patients With HER2-negative Breast Cancer With Liver Metastases
NCT07466927HER2-negative Breast Cancer
Fudan University
Phase 2
30
Shanghai
2026-03-15
Recruiting
Olive Oil Before Lung Cancer Surgery to Prevent Chylothorax
NCT07807696Lung Cancer, Chylothorax
Fudan University
Not applicable
1,036
Shanghai
2026-03-15
Recruiting
Study on Using TROP2-PET and 18F-FDG PET to Predict the Efficacy of Anti TROP2 ADC Treatment in Advanced Breast Cancer
NCT07471776Metastatic Breast Cancer ( HER2 Negative)
Fudan University
Phase 2
45
Shanghai
2026-03-11
Recruiting
SHR-1701 in Combination With Stereotactic Body Radiotherapy in mCRPC
NCT07451795Prostate Cancer, mCRPC (Metastatic Castration-resistant Prostate Cancer)
Fudan University
Phase 2
66
Fujian, Shanghai, Xiamen
2026-03-02
Recruiting
Comparison of Serplulimab Versus Nivolumab in Neoadjuvant Therapy for Resectable Stage II-IIIA Squamous NSCLC
NCT07398937Resectable Stage II-IIIa Squamous NSCLC
Fudan University
Phase 2
116
Shanghai
2026-02-05
Recruiting
Study of Radiotherapy Combined With Cisplatin/Carboplatin, Adebrelimab and Bevacizumab in the Treatment of TNBC-BM.
NCT07638852TNBC, Triple Negative Breast Cancer, Brain Metastasases
Fudan University
Phase 2
58
Shanghai
2026-02-02
Not yet open
Neoadjuvant Immunotherapy ยฑ Radiotherapy in MSI-H/dMMR Locally Advanced Colorectal Cancer
NCT07403877Colorectal Cancer (MSI-H)
Fudan University
Phase 2
114
Shanghai
2026-02-01
Not yet open
Integrated Clinical-molecular Risk Stratification to Early Recurrence in Colorectal Liver Metastases
NCT07391007Colorectal Liver Metastases
Fudan University
Observational
200
Shanghai
2026-01-31
Not yet open
Re-challenge Immunotherapy With Cromolyn, TQB2102, and Panpulimab in Immune-Refractory Triple Negative Breast Cancer
NCT07419880Triple -Negative Breast Cancer
Fudan University
Phase 2
46
Shanghai
2026-01-30
Recruiting
A Clinical Study of Sintilimab Combined With Chemothrapy Versus Chemotherapy as Adjuvant Therapy for Gastric/Gastroesophageal Junction Adenocarcinoma
NCT07492615Gastric Cancer or Gastroesophageal Junction Adenocarcinoma
Fudan University
Phase 2
276
Shanghai
2026-01-29
Recruiting
RWS of Tunlametinib in NRAS-Mutant Advanced Melanoma
NCT07445022Melanoma Advanced
Fudan University
Phase 4
110
Shanghai
2026-01-28
Not yet open
Clinical Study on the Use of Huaier Granules for the Treatment of Proteinuria Related to Bevacizumab and Anlotinib in Lung Cancer Patients
NCT07358520Proteinuria
Fudan University
Phase 4
40
Xuzhou, Shanghai
2026-01-28
Recruiting
Refining Fertility-sparing Treatment in Endometrial Carcinoma Based on Molecular Classification
NCT07319429Endometrial Cancer, Fertility
Fudan University
Phase 2/3
260
Shanghai
2026-01-25
Recruiting
A Platform Trial for Personalized and Adaptive Therapies in Hepatocellular Carcinoma
NCT07328009Hepato Cellular Carcinoma (HCC)
Fudan University
Phase 2
350
Shanghai
2026-01-19
Not yet open
Huaier Granule and Proteinuria
NCT07355361Proteinuria, Breast Cancer Patients
Fudan University
Phase 2
120
Shanghai
2026-01-15
Not yet open
Pucotenlimab Combined With Becotatug Vedotin in Advanced Cutaneous Squamous Cell Carcinoma
NCT07394244Cutaneous Squamous Cell Carcinoma (CSCC)
Fudan University
Phase 2
38
Shanghai
2026-01-09
Recruiting
Comparative Study on the Short- and Long-term Efficacy of Q-ISR, Traditional Sub-ISR, and t-ISR
NCT07371273Colorectal Cancer
Fudan University
Phase 2
100
Shanghai
2026-01-07
Active, closed
MRI-Driven Precision Typing and Response Prediction in Luminal Breast Cancer
NCT07692230HR Positive/HER-2 Negative Breast Cancer
Fudan University
Observational
2,000
Shanghai
2026-01-06
Recruiting
Sac-TMT Combined With Bevacizumab in TNBC With Brain Metastases
NCT07623577TNBC, Brain Metastasis
Fudan University
Phase 2
24
Shanghai
2026-01-01
Not yet open
Active Anti-diabetic Treatment Plus Chemotherapy for Pancreatic Cancer Related Diabetes
NCT07272109Pancreatic Cancer
Fudan University
Phase 3
210
Shanghai
2026-01-01
Recruiting
G-CSF Combined With IL-11 on Hematopoietic Reconstitution After Autologous Hematopoietic Stem Cell Transplantation
NCT07362810Mobilization of Hematopoietic Stem Cells (HSC) to Peripheral Blood (PB), Hematopoetic Stem Cell Transplantation, Hemato-oncologic Patients
Fudan University
Phase 2
224
Zhengzhou, Shanghai
2026-01-01
Recruiting
Dynamic Circulating Tumor DNA Monitoring to Guide Systemic Therapy in Gastric Cancer
NCT07517107Gastric Cancer
Fudan University
Phase 2
600
Shanghai
2026-01-01
Recruiting
Psychological State, Immunotherapy Response, and Multi-Omics Signatures in TNBC
NCT07290153Breast Cancer Female NOS, General Anxiety Disorder, Depressive Disorder
Fudan University
Observational
120
Shanghai
2026-01-01
Recruiting
Unrelated Cord Blood Transplantation for EBV-associated Lymphoproliferative Disorders
NCT07381738Epstein-Barr Virus-associated Lymphoproliferative Diseases, Chronic Active Epstein-Barr Virus Infection, EBV Associated Lymphoma, Umbilical Cord Blood Transplant
Fudan University
Phase 2
80
Shanghai
2026-01-01
Not yet open
AI for Renal Tumors Using Non-Contrast CT
NCT07304492Renal Neoplasms, Renal Cyst
Fudan University
Observational
10,000
Shanghai
2026-01
Not yet open
Chinese Herbal Therapy (Qiqi Shengmai Formula) for Moyamoya Vasculopathy: The CHIMES Trial
NCT07286110Moyamoya Disease, Moyamoya Syndrome
Fudan University
Phase 1
66
Shanghai
2025-12-30
Recruiting
ctDNA-guided Treatment Decision-making
NCT07394218Metastatic Breast Cancer ( HER2 Negative), ctDNA
Fudan University
Phase 2
122
Shanghai
2025-12-24
Recruiting
Station 4L Lymph Node Dissection Versus No Dissection in Clinical Stage I Solid Nodule-Type Invasive NSCLC
NCT07801430Non-Small Cell Lung Cancer
Fudan University
Not applicable
384
Shanghai
2025-12-15
Not yet open
Evaluating the Clinical Value of Transparent Cap-Assisted Second Examination of the Sigmoid Colon for Improving Colorectal Adenoma Detection Rates
NCT07261319Colorectal Adenoma
Fudan University
Not applicable
614
Shanghai
2025-12-15
Not yet open
Impact of Discontinuing GLP-1 Receptor Agonists for Two Weeks Prior to Upper Endoscopy on the Risk of Gastric Retention
NCT07276763Gastric Retention
Fudan University
Observational
16,509
Shanghai
2025-12-10
Recruiting
TITAN-HCC: Neoadjuvant and Adjuvant QL1706 With TACE in Resectable Hepatocellular Carcinoma Beyond Milan Criteria
NCT07268131Hepatocellular Carcinoma (HCC)
Fudan University
Not applicable
30
Shanghai
2025-12-09
Recruiting
DV+BCG in HER2-Expressing, BCG-Naรฏve High-Risk NMIBC
NCT07207824Bladder (Urothelial, Transitional Cell) Cancer, NMIBC
Fudan University
Phase 3
182
Shanghai
2025-12-01
Not yet open
CONVERT-HB1: Radical Prostatectomy After Systemic Therapy for High-volume Metastatic Hormone-sensitive Prostate Cancer
NCT07268794Metastatic Prostate Cancer, Prostate Cancer (Adenocarcinoma), Metastatic Hormone-Sensitive Prostate Cancer (mHSPC)
Fudan University
Phase 2
112
Shanghai
2025-11-30
Recruiting
Real-world Outcomes of Peripheral T-cell Lymphoma: A Multicenter Retrospective and Prospective Cohort Study
NCT07270861Peripheral T-Cell Lymphoma
Fudan University
Observational
3,000
Shanghai
2025-11-15
Recruiting
AK104 Plus Radiotherapy Combined With Standard Therapy Versus Standard Therapy as First-Line Treatment for pMMR/MSS CRLM (APSOC)
NCT07544784Colorectal Cancer Liver Metastases (CRLM)
Fudan University
Phase 2
73
Shanghai
2025-11-04
Recruiting
The Necessity of Surgery in Patients With mGC Achieving Radiological Response After Conversion Therapy
NCT07757165Advanced Metastatic Gastric Cancer
Fudan University
Phase 2
126
Shanghai
2025-11-01
Recruiting
Effect of OFA, OSA Versus Opioid-based Anesthesia on NETs and Cancer Cell Malignancy After Colorectal Cancer Surgery
NCT07264556Colorectal Cancer, Opioid-free Anesthesia, NETs
Fudan University
Not applicable
90
Shanghai
2025-11-01
Active, closed
Predictive Value of Exosomes in Pleural Effusion for Advanced Lung Cancer
NCT07262671NSCLC (Advanced Non-small Cell Lung Cancer)
Fudan University
Observational
100
Shanghai
2025-10-16
Recruiting
The Safety, Efficacy, and Immune Response of Multimodal Thermal Therapy in the Treatment of Malignant Liver Tumors
NCT07159048Hepatocellular Carcinoma, Colorectal Cancer Liver Metastasis
Fudan University
Not applicable
120
Shanghai
2025-10-15
Rows per page Showing 1–100 of 454
1 2 3 Next
Cite this view

Priya Life Science (2026). Clinical trial register: studies with a Chinese investigative site, filtered. Derived from ClinicalTrials.gov. Retrieved 24 September 2026. https://priyalifescience.com/clinical-trials-china/city/shanghai

Query this register directly
GET /api/trials?country=cn&status=recruiting&format=json Try it now →

About this register

This register is built from ClinicalTrials.gov, the trial registry run by the U.S. National Library of Medicine. It includes every study on the registry that lists at least one investigative site in China and is recruiting, not yet recruiting, active but no longer recruiting, or enrolling by invitation: 19,052 studies in total at the last sync on 22 Sep 2026, 11:10 UTC. The full list can be downloaded as CSV or queried as JSON through the register API.

This page shows the 454 of those studies with a site in Shanghai that also match the filters currently applied.

How many clinical trials are recruiting in Shanghai?

295 of the 454 studies on this page are recruiting new participants as of the 22 Sep 2026, 11:10 UTC sync. A further 104 have not yet opened recruitment, 49 are active but closed to new participants, and 6 are enrolling by invitation only. Eligibility for any study is decided by its study team.

Summary by phase

Studies by phase (Shanghai), 454 studies
PhaseStudiesRecruitingShare
Phase 220612745.4%
Observational835718.3%
Not applicable673914.8%
Phase 3584512.8%
Phase 1/219134.2%
Phase 41062.2%
Phase 2/3541.1%
Phase 1320.7%
Phase EARLY_PHASE1320.7%

Most active sponsors

Lead sponsors with the most studies (Shanghai)
Lead sponsorStudiesRecruiting
Fudan University454295
Listing here is informational and not medical advice; eligibility is determined by each study team. See also the Ireland, UK, EU, USA and India registers.